Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy



Status:Recruiting
Conditions:Insomnia Sleep Studies, Women's Studies, Pulmonary, Pulmonary
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases, Reproductive
Healthy:No
Age Range:18 - Any
Updated:2/22/2019
Start Date:July 20, 2018
End Date:June 2024
Contact:Rebecca Clifton, PhD
Email:rclifton@bsc.gwu.edu
Phone:301-881-9260

Use our guide to learn which trials are right for you!

A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

A randomized controlled trial of 2,700 women to assess whether treatment of obstructive sleep
apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction
in the rate of hypertensive disorders of pregnancy.

Emerging data support a link between sleep disordered breathing (SDB) and adverse pregnancy
outcomes. In particular, women with obstructive sleep apnea (OSA) appear to be at increased
risk of both hypertensive disorders of pregnancy and gestational diabetes. In the
non-pregnant population, OSA is typically treated with continuous positive airway pressure
(CPAP) during sleep and has been shown to reduce blood pressure in hypertensive patients.
Unfortunately, data on whether maternal and neonatal outcomes could be improved with
treatment of OSA during pregnancy are extremely limited. This study aims to address this
knowledge gap.

A randomized controlled trial of 2,700 women to assess whether treatment of obstructive sleep
apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction
in the rate of hypertensive disorders of pregnancy.

Inclusion Criteria:

1. Nulliparous (no prior delivery at or after 20 weeks 0 days of gestation).

2. Singleton gestation. Twin gestation reduced to singleton, either spontaneously or
therapeutically, is not eligible unless the reduction occurred before 14 weeks project
gestational age (see Section 3.4.2).

3. Gestational age at randomization between 16 weeks 0 days and 21 weeks 6 days based on
clinical information and evaluation of the earliest ultrasound as described in
Gestational Age Determination in Section 3.4.2

4. Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and <30.

Exclusion Criteria:

1. Previously prescribed, current or planned therapy for sleep apnea.

2. Age < 18 years, because the rate of sleep apnea in this population is extremely low.

3. Inability to sleep in a stable place with access to the CPAP machine at least 5 nights
per week.

4. Asthma requiring systemic steroid therapy for more than 14 days within the past 6
months because this population is expected to be unresponsive to CPAP therapy.

5. Current use of prescribed sleeping pills for insomnia.

6. Chronic medical conditions requiring oxygen supplementation (e.g. pulmonary fibrosis,
pulmonary hypertension, cystic fibrosis) because this population is expected to be
unresponsive to CPAP therapy.

7. Current use of antihypertensive medication because of the difficulty in diagnosing
superimposed preeclampsia.

8. Chronic renal disease with serum creatinine >1.3 mg/dL because the primary outcome
would be pre-determined.

9. Antiphospholipid antibody syndrome, because it would compromise the primary outcome
diagnosis.

10. History of medical complications such as:

1. Active liver disease (acute hepatitis, chronic active hepatitis, persistently
abnormal liver enzymes)

2. Thrombocytopenia with platelet count <100,000 because of the difficulty in
assessing the primary outcome.

11. Active vaginal bleeding (more than spotting) at the time of randomization.

12. Known chromosomal, genetic, major malformations or fetal demise, or planned
termination of pregnancy because inclusion would compromise evaluation of secondary
neonatal outcomes.

13. Known major uterine malformations associated with adverse pregnancy outcomes.

14. Current use of opiates (heroin, methadone, or other daily opioid use) due to
inaccuracy of the home sleep test and inefficiency of CPAP.

15. Active drug use, alcohol use, or unstable psychiatric condition.

16. Participation in another interventional study that influences preeclampsia,
hypertensive disorders of pregnancy, or GDM.

17. Prenatal care or delivery planned at a non-network center.
We found this trial at
12
sites
Houston, Texas 77030
Principal Investigator: Suneet Chauhan, MD
Phone: 713-500-6467
?
mi
from
Houston, TX
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Alan TN Tita, MD
Phone: 205-996-6262
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: John M Thorp, MD
Phone: 919-350-6117
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: George R Saade, MD
Phone: 409-772-0312
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Cynthia Gyamfi-Bannerman, MD
Phone: 212-305-4348
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Samuel Parry, MD
Phone: 212-662-3926
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: William Grobman, MD
Phone: 312-503-3200
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44109
Principal Investigator: Edward Chien, MD
Phone: 216-778-7533
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Mark Landon, MD
Phone: 614-685-3229
?
mi
from
Columbus, OH
Click here to add this to my saved trials
300 Halket St.
Pittsburgh, Pennsylvania 15213
1-866-MyMagee (696-2433)
Principal Investigator: Hyagriv Simhan, MD
Phone: 412-641-4072
Magee-Womens Hospital of UPMC Magee-Womens Hospital of UPMC is a world-class center for both women's...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Providence, Rhode Island 02903
Principal Investigator: Dwight J Rouse, MD
Phone: 401-274-1122
?
mi
from
Providence, RI
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Michael W Varner, MD
Phone: 801-585-7645
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials